AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors
20250004
Phase 1 other active
Quick answer
AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors for microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) solid tumors is a Phase 1 program (other) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen Technology (Ireland) UC
- Indication
- microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) solid tumors
- Phase
- Phase 1
- Modality
- other
- Status
- active